Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-Specific IgG but Not Autoantibodies in Pemphigus Vulgaris
- 1 September 2009
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 129 (9), 2202-2210
- https://doi.org/10.1038/jid.2009.27
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in miceProceedings of the National Academy of Sciences, 2007
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinNew England Journal of Medicine, 2006
- BAFF, APRIL and their receptors: Structure, function and signalingSeminars in Immunology, 2006
- B cells move to centre stage: novel opportunities for autoimmune disease treatmentNature Reviews Drug Discovery, 2006
- Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgarisBritish Journal of Dermatology, 2006
- Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapseArthritis & Rheumatism, 2006
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003
- BAFF selectively enhances the survival of plasmablasts generated from human memory B cellsJCI Insight, 2003
- Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatmentJournal of the American Academy of Dermatology, 2001
- Autoimmunity against desmosomal cadherins in pemphigusJournal of Dermatological Science, 1999